FDA Expects Closing Gap On NDI Notifications To Open Window Wider On Supplements Sold In US

FDA regulatory framework for VMS product manufacturing and marketing provides little pre-market transparency into what’s available in US, but it’s clear from post-market monitoring by the Office of Dietary Supplement Programs that compliance with the NDI notification requirement is lax.

• Source: Shutterstock

More from Regulation

More from Policy & Regulation